Assertio Holdings (ASRT): +66% Surge in 30 Days on Earnings Beat and Oncology Growth
Key Takeaways
- ASRT stock surged +66% over the past 30 days, driven by strong Q4 2025 earnings beat and optimistic 2026 guidance highlighting Rolvedon growth.
- Over the past quarter, the stock rose +117%, fueled by improving gross margins, stable product demand, and analyst price target increases.
- Key drivers include earnings outperformance, with adjusted EPS loss narrower than expected, revenue beat, and focus on high-margin oncology products like Rolvedon.
- Gross margin expansion to 75% in Q4 and projected adjusted EBITDA of $28M-$40M for 2026 boosted investor sentiment.
- Analyst targets averaging around $35-$38 signal significant upside potential amid portfolio optimization.
Understanding Assertio Holdings (ASRT) and Its Place in the Market
Assertio Holdings, Inc. (ASRT) operates as a commercial-stage pharmaceutical company focused on branded prescription products targeting neurology, oncology, pain, and inflammation. The company's approach centers on acquiring, licensing, and commercializing differentiated therapies through an efficient omni-channel strategy that includes digital marketing, field sales, and market access capabilities. Its portfolio features key products like Rolvedon (efpegpegfilgrastim), a long-acting granulocyte colony-stimulating factor used in oncology to reduce febrile neutropenia; Sympazan, a benzodiazepine for seizures in Lennox-Gastaut syndrome; Indocin (indomethacin), an NSAID for arthritis and gout; and others such as Cambia and Sprrix for migraine and pain management.
In the specialty pharma space, ASRT maintains a solid foothold in niche areas, especially with Rolvedon leading in Medicare Part B clinic share. From what I see, this combination of high-growth oncology exposure and stable neurology offerings has contributed to the recent stock strength, particularly as management emphasizes capital-efficient growth in its oncology franchise alongside improving fundamentals like 75% gross margins.
ASRT Stock Performance: Breaking Down the Last 30 Days and Quarter
In the past 30 days, ASRT stock rose from around $12—closing at $11.95 on March 5—to $19.88, delivering a +66% gain. The move was marked by volatility and clear upward trends, with notable accelerations following the Q4 earnings release on March 16, including multi-day jumps of 12-18% on peak volume days surpassing 400,000 shares.
Looking at the quarter, from a January 2 close of $9.14 to the current $19.88, the stock gained +117%. This progress included steady climbs from January lows, picking up speed in March as consolidation around $11-12 broke out toward highs near $20.45, indicating persistent buyer interest and strength relative to broader medical sector peers.
The Key Catalyst Behind ASRT's Recent 30-Day Rally
The main driver was Assertio's Q4 and full-year 2025 earnings on March 16, reporting an adjusted EPS loss of -$1.86—much better than the consensus -$3.05 (a 39% surprise)—and revenue of $13.54 million, exceeding expectations by 185% even with a year-over-year drop. Gross margins climbed to 75% from 61%, thanks to a higher Indocin mix and no repeat inventory write-downs.
Looking ahead, 2026 guidance projected net product sales of $110M-$125M and adjusted EBITDA of $28M-$40M, spotlighting Rolvedon as the primary growth driver with normalized sales expected in Q2 after integration and steady demand. Sympazan sales increased to $3.1M (up 24%), helping offset Rolvedon's Q4 timing at $0.4M. Analysts responded positively, with HC Wainwright lifting its target from $3 to $35 (Buy rating), pushing consensus to $35-$38 and suggesting over 75% upside. In my view, the market's enthusiasm for the oncology focus and cost controls fueled the post-earnings momentum.
I also checked this using Tickeron’s AI Screener to gauge how ASRT stacks up against industry peers on margins and growth metrics.
Building the Case for ASRT's +117% Quarterly Gain
The quarter's +117% advance stemmed from portfolio stabilization and strategic shifts. Rolvedon achieved full-year sales of $68.2M despite Q4 softness due to sell-in timing, while retaining market share leadership. Sympazan grew steadily on volume and payer mix, and Indocin remained stable at $5.5M quarterly, countering generic pressure with pricing support.
Broader factors like strong oncology demand and payer expansions aided the rebound from early-year lows near $9. Institutional buying picked up as YTD returns topped 100%, surpassing the S&P 500. Sector tailwinds in specialty pharma, paired with Assertio's margin improvements (TTM revenue $118.71M, rising EBITDA), built momentum. The earnings beat and guidance ultimately solidified these trends, sparking the biggest moves.
Discovering an Edge with Trending AI Robots
In my own trading and research, I often turn to Tickeron’s Trending AI Robots to identify top performers among hundreds of bots trading thousands of tickers. This page curates bots with the best recent results, tying into current trends through metrics like win rate, average return, and Sharpe ratio. Whether it's momentum plays, mean reversion, or neural network forecasts—from day trades to swings—the detailed backtests and live stats help me pick strategies that fit my risk profile and goals. One thing that stands out is how accessible it makes testing these tools to potentially sharpen my edge.
What's Next for ASRT: Key Drivers and Watchpoints
I'm watching Q1 2026 earnings closely for Rolvedon sales normalization after the label transition and Sympazan volume trends. Developments in oncology support therapies, such as payer formulary updates for Rolvedon, could impact access and adoption. Macro elements like healthcare spending and biosimilar competition will matter too. Progress on oncology expansion through targeted licensing, plus EBITDA heading toward $28M-$40M, should influence sentiment. Risks involve Indocin generic erosion and Rolvedon execution, while catalysts might come from analyst revisions or partnerships. This is important because it frames the stock's path amid ongoing portfolio refinement.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
ASRT sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for ASRT moved above the 200-day moving average on March 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ASRT advanced for three days, in of 247 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 221 cases where ASRT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for ASRT moved out of overbought territory on April 07, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on April 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ASRT as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ASRT turned negative on April 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASRT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ASRT broke above its upper Bollinger Band on March 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ASRT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.238) is normal, around the industry mean (29.131). P/E Ratio (0.000) is within average values for comparable stocks, (64.184). Projected Growth (PEG Ratio) (0.895) is also within normal values, averaging (2.048). ASRT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (0.972) is also within normal values, averaging (110.499).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASRT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsGeneric
Advertisement